Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab and Remdesivir in COVID-19
NCT04690920Completed
- Sponsor
- The University of Lahore
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of tocilizumab and remdesivir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by The University of Lahore. Primary endpoint: Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen at 7 days. Started Jul 2020; status: completed.
02
Drugs
tocilizumabremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04690920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690920.